Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs
- 作者: Korolev M.1, Letyagina E.1, Sizikov A.2, Bogoderova L.3, Ubshaeva Y.1, Omelchenko V.1, Akimova A.1, Mullagaliev A.1, Chumasova O.2, Kurochkina Y.1
-
隶属关系:
- Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
- Research Institute of Fundamental and Clinical Immunology
- State Novosibirsk Regional Clinical Hospital
- 期: 卷 94, 编号 5 (2022)
- 页面: 636-641
- 栏目: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/108780
- DOI: https://doi.org/10.26442/00403660.2022.05.201502
- ID: 108780
如何引用文章
全文:
详细
Background. Currently, observations are accumulating indicating the negative effect of therapy with a number of biologic disease-modifying anti-rheumatic drugs (bDMARDs) drugs on the course of COVID-19. These facts determine the relevance of studying the factors of severe course and unfavorable outcome in immuno-inflammatory rheumatic diseases (IIRD) patients treated with bDMARDs in order to develop tactics for managing this category of patients in a pandemic.
Aim. To evaluate the influence of clinical and demographic factors on the risk of development, severity of the course and clinical outcomes of a new coronavirus infection in patients suffering from IIRD and receiving therapy with genetically engineered biological drugs.
Materials and methods. A retrospective analysis of the database of the register of patients with IIRD receiving bDMARDs in the Novosibirsk region was performed, which included 318 patients, 94 of whom had indications of having suffered viral infection/pneumonia for the period from 01.04.2020 to 31.12.2020.
Results. According to the data obtained, at the time of the analysis, 94 people out of 318 patients with IIRD had a new coronavirus infection. Most (53%) of the patients had a mild infection. At the same time, the nosological form, the use of anti-rheumatic drugs and glucocorticoids did not increase the risks of severe coronavirus infection. When using bDMARDs, only anti-B-cell therapy (rituximab) associated with statistically significant increase in the risk of severe/extremely severe COVID-19. The mortality rate according to the analysis of the register was 6,38%.
Conclusion. Patients with IIRD have a high risk of severe coronavirus infection, while the severity of the disease is associated with the type of therapy performed.
作者简介
Maxim Korolev
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
Email: juli_k@bk.ru
ORCID iD: 0000-0002-4890-0847
канд. мед. наук, зам. рук., врач-ревматолог, зав. лаб. патологии соединительной ткани НИИКЭЛ – филиала ИЦиГ СО РАН, гл. внештатный ревматолог Минздрава Новосибирской области
俄罗斯联邦, NovosibirskElena Letyagina
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
Email: juli_k@bk.ru
ORCID iD: 0000-0002-6275-2924
канд. мед. наук, зав. отд-нием ревматологии, ст. науч. сотр. лаб. патологии соединительной ткани НИИКЭЛ – филиала ИЦиГ СО РАН
俄罗斯联邦, NovosibirskAlexey Sizikov
Research Institute of Fundamental and Clinical Immunology
Email: juli_k@bk.ru
ORCID iD: 0000-0002-7213-7482
канд. мед. наук, зав. отд-нием ревматологии ФГБНУ НИИФКИ
俄罗斯联邦, NovosibirskLarisa Bogoderova
State Novosibirsk Regional Clinical Hospital
Email: juli_k@bk.ru
ORCID iD: 0000-0002-2570-8035
зав. отд-нием ревматологии ГБУЗ НСО ГНОКБ
俄罗斯联邦, NovosibirskYuliya Ubshaeva
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
Email: juli_k@bk.ru
ORCID iD: 0000-0001-6330-1044
канд. мед. наук, врач-ревматолог, науч. сотр. лаб. патологии соединительной ткани НИИКЭЛ – филиала ИЦиГ СО РАН
俄罗斯联邦, NovosibirskVitaly Omelchenko
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
Email: juli_k@bk.ru
ORCID iD: 0000-0001-6606-7185
канд. мед. наук, врач-ревматолог, науч. сотр. лаб. патологии соединительной ткани НИИКЭЛ – филиала ИЦиГ СО РАН
俄罗斯联邦, NovosibirskAnna Akimova
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
Email: juli_k@bk.ru
ORCID iD: 0000-0003-1099-3256
врач-ревматолог отд-ния ревматологии, мл. науч. сотр. лаб. патологии соединительной ткани НИИКЭЛ – филиала ИЦиГ СО РАН
俄罗斯联邦, NovosibirskArsen Mullagaliev
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
Email: juli_k@bk.ru
ORCID iD: 0000-0002-5213-5658
мл. науч. сотр. лаб. фармакологического моделирования и скрининга биоактивных молекул НИИКЭЛ – филиала ИЦиГ СО РАН
俄罗斯联邦, NovosibirskOksana Chumasova
Research Institute of Fundamental and Clinical Immunology
Email: juli_k@bk.ru
ORCID iD: 0000-0003-3797-6392
канд. мед. наук, врач-ревматолог ФГБНУ НИИФКИ
俄罗斯联邦, NovosibirskYuliya Kurochkina
Research Institute of Clinical and Experimental Lymphology – Branch of Federal Research Center "Institute of Cytology and Genetics"
编辑信件的主要联系方式.
Email: juli_k@bk.ru
ORCID iD: 0000-0002-7080-777X
канд. мед. наук, врач-ревматолог отд-ния ревматологии, науч. сотр. лаб. патологии соединительной ткани НИИКЭЛ – филиала ИЦиГ СО РАН
俄罗斯联邦, Novosibirsk参考
- Белов Б.С. Терапия генно-инженерными биологическими препаратами и инфекции у больных ревматоидным артритом: актуальность и перспективы. Научно-практическая ревматология. 2014;52(3):322-30 [Belov BS. Biological therapy and infections in patients with rheumatoid arthritis: relevance and prospectsitle. Rheumatology Science and Practice. 2014;52(3):332-30 (in Russian)].
- Насонов Е.Л. Коронавирусная болезнь 2019 (COVID-19): размышления ревматолога. Научно-практическая ревматология. 2020;58(2):123-32 [Nasonov EL. Coronavirus Disease 2019 (COVID-19): a rheumatologist’s thoughts. Rheumatology Science and Practice. 2020;58(2):123-32 (in Russian)]. doi: 10.14412/1995-4484-2020-123-132
- Liu M, Gao Y, Zhang Y, et al. The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis. J Infect. 2020;81(3):e93-5. doi: 10.1016/j.jinf.2020.05.065
- Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6. doi: 10.1038/s41586-020-2521-4
- Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-66. doi: 10.1136/annrheumdis-2020-217871
- Kow CS, Hasan SS. Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. Rheumatol Int. 2020;40(12):2117-8. doi: 10.1007/s00296-020-04715-0
- Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. Arthritis Rheumatol. 2021;73(2). doi: 10.1002/art.41596
- Насонов Е.Л., Лила А.М., Мазуров В.И., и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-54 [Nasonov EL, Lila AM, Mazurov VI, et al. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Rheumatology Science and Practice. 2021;59(3):239-54 (in Russian)]. doi: 10.47360/1995-4484-2021-239-254
- Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882
- Calabrese L, Winthrop KL. Rheumatology and COVID-19 at 1 year: facing the unknowns. Ann Rheum Dis. 2021;80(6):679-81. doi: 10.1136/annrheumdis-2021-219957
- Насонов Е.Л., Авдеева А.С. Деплеция В-клеток при иммуновоспалительных ревматических заболеваниях и коронавирусная болезнь 2019 (COVID-19). Научно-практическая ревматология. 2021;59(4):384-93 [Nasonov EL, Avdeeva AS. B cell depletion in immunoinflammatory rheumatic diseases and coronavirus disease 2019 (COVID-19). Rheumatology Science and Practice. 2021;59(4):384-93 (in Russian)]. doi: 10.47360/1995-4484-2021-384-393